Feb 25, 2020 09:10 JST
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
TOKYO, Feb 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.
Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in China from FUJI YAKUHIN. FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai. Eisai will be responsible for a New Drug Application for dotinurad in China and pay FUJI YAKUHIN upfront payment, development milestone and sales milestone.
Hyperuricemia is the second most common metabolic disease after diabetes mellitus in China. In addition, hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout.
Furthermore, it is estimated that currently in China, the number of patients with hyperuricemia is approximately 190 million and the number of patients with gout is approximately 16 million.(1) It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socio-economic development in China.
Dotinurad is a new therapeutic agent for gout and hyperuricemia discovered by FUJI YAKUHIN. Dotinurad suppresses uric acid reabsorption and lowers blood uric acid levels, by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney.
Under this agreement, Eisai will proceed with the development of dotinurad in China. Following commercialization, Eisai will aim to contribute to patients with hyperuricemia that are unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. FUJI YAKUHIN anticipates maximizing the value of dotinurad in China by leveraging Eisai's business base as the first step in the global expansion of dotinurad. Through the development and commercialization of dotinurad, Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in China and contribute to improving the quality of life of patients.
About Eisai Co., Ltd.
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.
For further information on Eisai Co., Ltd., please visit https://www.eisai.com.
About FUJI YAKUHIN CO., LTD.
FUJI YAKUHIN CO., LTD. is a complex pharmaceutical company with an integrated manufacturing and sales system consisting of ethical drug sales, placement drug sales, drugstore business, and the pharmaceutical manufacturing business that supports them. Regarding ethical drugs, FUJI YAKUHIN has created two drugs with different mechanisms of action, topiroxostat and dotinurad, for gout and hyperuricemia.
For further information on FUJI YAKUHIN CO., LTD., please visit https://www.fujiyakuhin.co.jp/ (Japanese only)
URAT1 and has a small effect on other transporters, so it reduces serum uric acid levels at lower doses. Dotinurad is expected to have a low risk of side effects and drug interaction.
In Japan, on January 23, 2020, FUJI YAKUHIN CO., LTD. obtained manufacturing and marketing approval for dotinurad.
(1) For the estimated data regarding the number of patients with hyperuricemia as well as the number of patients with gout:
- Dataofmorbidityprevalencerate-RuiLiuetal., PrevalenceofHyperuricemiaandGoutinMainlandChinafrom2000to
2014: A Systematic Review and Meta-Analysis, BioMed Research International, Volume 2015, Article ID 762820
- Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL: http://www.un.org/en/development/desa/population/
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com
Eisai Co., Ltd.
Public Relations Department
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
MHI Thermal Systems Launches New Air Conditioner Ads on Concept of "Comforting the World with Heat," Featuring Popular Actress Keiko Kitagawa
Apr 09, 2020 13:39 JST
MHPS: Second Commercial-use MEGAMIE System Begins Operations at HAZAMA ANDO Technical Research Institute
Apr 09, 2020 13:09 JST
Mazda Earns Six IIHS Top Safety Pick+ Awards, the Most Among Automakers Tested for 2020
Apr 08, 2020 11:56 JST
Toyota Motor Corp. and Toyota Group Companies outline efforts towards COVID-19
Apr 07, 2020 15:07 JST
Azabu Insights: Survey Shows 34% increase in Mask Usage in Tokyo
Apr 06, 2020 05:45 JST
Toyota Green Energy Established to Conduct Renewable Energy Power Generation Business
Apr 03, 2020 17:30 JST
Toyota Awarded the 66th Okochi Memorial Production Prize for the Development of an Aluminum Casting Technology
Apr 03, 2020 14:36 JST
Mazda Taking Pre-orders for its 100th Anniversary Special Edition Series in Japan
Apr 03, 2020 12:47 JST
General Motors and Honda to Jointly Develop Next-Generation Honda Electric Vehicles Powered by GM's Ultium Batteries
Apr 03, 2020 09:50 JST
BYD, Toyota Launch BYD TOYOTA EV TECHNOLOGY Joint Venture to Conduct Battery Electric Vehicle R&D
Apr 02, 2020 17:25 JST
Mitsubishi Motors Announces Temporary Production Suspension at a Plant in Japan
Apr 02, 2020 15:10 JST
MHPS: World's Most Efficient Power Plant is Synced to the Grid and Operating at Full Load, Ahead of Schedule
Apr 02, 2020 11:05 JST
Hitachi Announces Establishment of Hitachi Industrial Holdings Americas, Inc. to Strengthen the Industry Business in North America
Apr 01, 2020 17:17 JST
DENSO Invests in Certhon Group, a greenhouse provider based in the Netherlands
Apr 01, 2020 16:52 JST
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
Apr 01, 2020 16:23 JST
DENSO and Tokyo Tech Establish DENSO Mobility Collaborative Research Cluster
Apr 01, 2020 14:47 JST
NEC Charts Global Growth by Appointing New CEO of Indian Business
Apr 01, 2020 13:17 JST
Outline of Showa Denko CEO Message to Newly-hired Employees
Apr 01, 2020 12:30 JST
DENSO Delivers Technical Support in D-WAVE Project using Quantum Systems to Combat COVID-19
Mar 31, 2020 19:03 JST
MHI Announces Nominations for Outside Directors
Mar 31, 2020 16:13 JST